Syndax Pharmaceuticals, Inc.2024财年第三财季实现净利润-84.13百万美元，同比减少64.48%

市场透视11-11

11月11日，Syndax Pharmaceuticals, Inc.（SNDX.US）公布财报，公告显示公司2024财年第三财季净利润为-84.13百万美元，同比减少64.48%；其中营业收入为12.50百万美元，每股基本收益为-0.98美元。从资产负债表来看，Syndax Pharmaceuticals, Inc.（SNDX.US）总负债59.38百万美元，其中短期债务852000.00美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482267314?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-11 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2482267314","market":"us","top_or_hot":-1,"title":"Syndax Pharmaceuticals, Inc.2024财年第三财季实现净利润-84.13百万美元，同比减少64.48%","media":"市场透视","content":"<div>\n<p>11月11日，Syndax Pharmaceuticals, Inc.（SNDX.US）公布财报，公告显示公司2024财年第三财季净利润为-84.13百万美元，同比减少64.48%；其中营业收入为12.50百万美元，每股基本收益为-0.98美元。从资产负债表来看，Syndax Pharmaceuticals, Inc.（SNDX.US）总负债59.38百万美元，其中短期债务852000.00美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000212abb36320&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syndax Pharmaceuticals, Inc.2024财年第三财季实现净利润-84.13百万美元，同比减少64.48%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyndax Pharmaceuticals, Inc.2024财年第三财季实现净利润-84.13百万美元，同比减少64.48%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000212abb36320&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月11日，Syndax Pharmaceuticals, Inc.（SNDX.US）公布财报，公告显示公司2024财年第三财季净利润为-84.13百万美元，同比减少64.48%；其中营业收入为12.50百万美元，每股基本收益为-0.98美元。从资产负债表来看，Syndax Pharmaceuticals, Inc.（SNDX.US）总负债59.38百万美元，其中短期债务852000.00美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000212abb36320&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNDX","symbol_name":"Syndax Pharmaceuticals, Inc. ","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000212abb36320&s=b","article_id":"2482267314","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000212abb36320&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2482267314","pubTimestamp":1731254493,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月11日，Syndax Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为-84.13百万美元，同比减少64.48%；其中营业收入为12.50百万美元，每股基本收益为-0.98美元。机构评级：截至2024年11月11日，当前有14家机构对Syndax Pharmaceuticals, Inc.目标价做出预测，其中目标均价为35.86美元，其中最低目标价为23.00美元，最高目标价为47.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"SNDX":"Syndax Pharmaceuticals, Inc. "},"translate_title":"Syndax Pharmaceuticals, Inc. achieved net profit of-$84.13 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 64.48%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":1},"content_text":"11月11日，Syndax Pharmaceuticals, Inc.（SNDX.US）公布财报，公告显示公司2024财年第三财季净利润为-84.13百万美元，同比减少64.48%；其中营业收入为12.50百万美元，每股基本收益为-0.98美元。从资产负债表来看，Syndax Pharmaceuticals, Inc.（SNDX.US）总负债59.38百万美元，其中短期债务852000.00美元，资产负债比为0.08，流动比率为0.07。机构评级：截至2024年11月11日，当前有14家机构对Syndax Pharmaceuticals, Inc.目标价做出预测，其中目标均价为35.86美元，其中最低目标价为23.00美元，最高目标价为47.00美元。公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。该公司的候选产品是对癌细胞和免疫调节细胞具有直接作用的恩替司他，以及SNDX-6352和SNDX-6352, 这是一种抗CSF-1R单克隆抗体，用于增强人体对免疫疗法已显示出耐药性的肿瘤的免疫反应。本集团的业务活动主要在美国地区开展。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482267314"}